Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2026)

Denali Therapeutics (DNLI) reported Cash from Financing Activities of $219.0 million for Q1 2026, up 5922.54% year-over-year from $3.6 million in Q1 2025, and up 14.01% on a QoQ basis from $192.1 million in Q4 2025.

Denali Therapeutics (DNLI) has 10 years of Cash from Financing Activities data on file, last reported at $219.0 million in Q1 2026.

  • Quarterly Cash from Financing Activities rose 5922.54% year-over-year to $219.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $412.0 million (up 2187.98% YoY) and the FY2025 annual result came in at $189.2 million, down 60.93% from the prior year.
  • Cash from Financing Activities rose to $219.0 million in Q1 2026 per DNLI's latest filing, from $192.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $500.3 million in Q1 2024 and bottomed at -$18.6 million in Q3 2024.
  • The 5-year median for Cash from Financing Activities is $4.4 million (2022), against an average of $71.8 million.
  • Peak annual rise in Cash from Financing Activities reached 31089.21% in 2024, while the deepest fall reached 844.74% in 2024.
  • Tracing DNLI's Cash from Financing Activities over 5 years: stood at $299.7 million in 2022, then sank by 98.43% to $4.7 million in 2023, then tumbled by 188.59% to -$4.2 million in 2024, then surged by 4709.72% to $192.1 million in 2025, then climbed by 14.01% to $219.0 million in 2026.
  • Per Business Quant, the three latest DNLI Cash from Financing Activities figures stand at $219.0 million (Q1 2026), $192.1 million (Q4 2025), and -$778000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Denali Therapeutics 3.82 Bn 3.82 Bn - 219.04 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 219.04 Mn
Mar 31, 2026 219.04 Mn
Dec 31, 2025 192.13 Mn
Dec 31, 2025 192.13 Mn
Sep 30, 2025 -778,000.00
Sep 30, 2025 -778,000.00
Jun 30, 2025 1.62 Mn
Jun 30, 2025 1.62 Mn
Mar 31, 2025 -3.76 Mn
Mar 31, 2025 -3.76 Mn
Dec 31, 2024 -4.17 Mn
Dec 31, 2024 -4.17 Mn
Sep 30, 2024 -18.56 Mn
Sep 30, 2024 -18.56 Mn
Jun 30, 2024 6.76 Mn
Jun 30, 2024 6.76 Mn
Mar 31, 2024 500.28 Mn
Mar 31, 2024 500.28 Mn
Dec 31, 2023 4.71 Mn
Dec 31, 2023 4.71 Mn
Sep 30, 2023 2.49 Mn
Sep 30, 2023 2.49 Mn
Jun 30, 2023 9.02 Mn
Jun 30, 2023 9.02 Mn
Mar 31, 2023 1.60 Mn
Mar 31, 2023 1.60 Mn
Dec 31, 2022 299.65 Mn
Dec 31, 2022 299.65 Mn
Sep 30, 2022 5.15 Mn
Sep 30, 2022 5.15 Mn
Jun 30, 2022 4.40 Mn
Jun 30, 2022 4.40 Mn
Mar 31, 2022 1.46 Mn
Mar 31, 2022 1.46 Mn
Dec 31, 2021 5.17 Mn
Dec 31, 2021 5.17 Mn
Sep 30, 2021 3.32 Mn
Sep 30, 2021 3.32 Mn
Jun 30, 2021 7.04 Mn
Jun 30, 2021 7.04 Mn
Mar 31, 2021 3.82 Mn
Mar 31, 2021 3.82 Mn
Dec 31, 2020 9.52 Mn
Dec 31, 2020 9.52 Mn
Sep 30, 2020 425.90 Mn
Sep 30, 2020 425.90 Mn
Jun 30, 2020 3.42 Mn
Jun 30, 2020 3.42 Mn
Mar 31, 2020 195.91 Mn
Mar 31, 2020 195.91 Mn
Sep 30, 2019 4.16 Mn
Sep 30, 2019 4.16 Mn
Jun 30, 2019 2.57 Mn
Jun 30, 2019 2.57 Mn
Mar 31, 2019 908,000.00
Mar 31, 2019 908,000.00
Dec 31, 2018 1.69 Mn
Dec 31, 2018 1.69 Mn
Sep 30, 2018 658,000.00
Sep 30, 2018 658,000.00
Jun 30, 2018 1.43 Mn
Jun 30, 2018 1.43 Mn
Mar 31, 2018 93.24 Mn
Mar 31, 2018 93.24 Mn
Dec 31, 2017 295.59 Mn
Dec 31, 2017 295.59 Mn
Sep 30, 2017 357,000.00
Sep 30, 2017 357,000.00
Jun 30, 2017 51,000.00
Jun 30, 2017 51,000.00
Mar 31, 2017 324,000.00
Mar 31, 2017 324,000.00